Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-two analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eighteen have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $142.00.
A number of research firms recently weighed in on RYTM. Canaccord Genuity Group set a $154.00 target price on Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Guggenheim lifted their price objective on shares of Rhythm Pharmaceuticals from $143.00 to $147.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. William Blair assumed coverage on shares of Rhythm Pharmaceuticals in a report on Friday, October 16th. They issued an "outperform" rating on the stock. Wolfe Research started coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, September 17th. They issued an "outperform" rating on the stock. Finally, Citizens Jmp raised their target price on shares of Rhythm Pharmaceuticals from $160.00 to $166.00 and gave the stock a "market outperform" rating in a research note on Wednesday, November 4th.
Read Our Latest Stock Report on Rhythm Pharmaceuticals
Insider Buying and Selling at Rhythm Pharmaceuticals
In related news, Director Christophe Jean sold 10,000 shares of the company's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $109.66, for a total transaction of $1,096,600.00. Following the sale, the director owned 11,712 shares in the company, valued at $1,284,337.92. This represents a 46.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter C. Smith sold 62,774 shares of the company's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $105.46, for a total value of $6,620,146.04. Following the transaction, the chief financial officer directly owned 114,024 shares in the company, valued at approximately $12,024,971.04. This trade represents a 35.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 122,774 shares of company stock valued at $12,850,246. 5.90% of the stock is currently owned by corporate insiders.
Institutional Trading of Rhythm Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of RYTM. BlackRock Inc. purchased a new stake in shares of Rhythm Pharmaceuticals during the 2nd quarter worth approximately $683,601,000. Primecap Management Co. CA purchased a new position in Rhythm Pharmaceuticals in the second quarter valued at approximately $351,838,000. Checkpoint Capital L.P. lifted its stake in Rhythm Pharmaceuticals by 2.6% in the third quarter. Checkpoint Capital L.P. now owns 1,216,574 shares of the company's stock valued at $115,836,000 after purchasing an additional 30,574 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in Rhythm Pharmaceuticals by 2.0% during the third quarter. Pictet Asset Management Holding SA now owns 976,487 shares of the company's stock valued at $93,019,000 after purchasing an additional 18,702 shares during the period. Finally, Jupiter Topco LLC bought a new position in Rhythm Pharmaceuticals during the second quarter valued at $102,752,000.
Rhythm Pharmaceuticals Stock Performance
Shares of RYTM opened at $119.04 on Thursday. The stock has a 50 day simple moving average of $97.63 and a 200 day simple moving average of $97.61. Rhythm Pharmaceuticals has a 52-week low of $74.50 and a 52-week high of $122.20. The firm has a market capitalization of $8.25 billion, a PE ratio of -41.05 and a beta of 2.17.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.10. Rhythm Pharmaceuticals had a negative net margin of 69.03% and a negative return on equity of 171.16%. The company had revenue of $92.13 million for the quarter, compared to the consensus estimate of $85.56 million. During the same period last year, the company earned ($0.82) earnings per share. The firm's revenue was up 79.6% compared to the same quarter last year. Equities research analysts predict that Rhythm Pharmaceuticals will post -4.90 EPS for the current fiscal year.
Rhythm Pharmaceuticals Company Profile
(
Get Free Report)
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rhythm Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.
While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.